RU2008114304A - Ингибирование вирусной экспрессии генов с использованием малой интерферирующей рнк - Google Patents

Ингибирование вирусной экспрессии генов с использованием малой интерферирующей рнк Download PDF

Info

Publication number
RU2008114304A
RU2008114304A RU2008114304/13A RU2008114304A RU2008114304A RU 2008114304 A RU2008114304 A RU 2008114304A RU 2008114304/13 A RU2008114304/13 A RU 2008114304/13A RU 2008114304 A RU2008114304 A RU 2008114304A RU 2008114304 A RU2008114304 A RU 2008114304A
Authority
RU
Russia
Prior art keywords
seq
sequence
rna
small interfering
nucleotides
Prior art date
Application number
RU2008114304/13A
Other languages
English (en)
Russian (ru)
Inventor
Роджер Л. КАСПАР (US)
Роджер Л. КАСПАР
Хейни ИЛЬВЕС (US)
Хейни ИЛЬВЕС
Аттила А. СЕЙХАН (US)
Аттила А. СЕЙХАН
Александр В. ВЛАССОВ (US)
Александр В. ВЛАССОВ
Брайан Х. ДЖОНСТОН (US)
Брайан Х. ДЖОНСТОН
Original Assignee
Сомадженикс Инк. (Us)
Сомадженикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/032768 external-priority patent/WO2006031901A2/en
Application filed by Сомадженикс Инк. (Us), Сомадженикс Инк. filed Critical Сомадженикс Инк. (Us)
Publication of RU2008114304A publication Critical patent/RU2008114304A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2008114304/13A 2005-09-12 2006-06-01 Ингибирование вирусной экспрессии генов с использованием малой интерферирующей рнк RU2008114304A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2005/032768 WO2006031901A2 (en) 2004-09-10 2005-09-12 SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
USPCT/US2005/032768 2005-09-12

Publications (1)

Publication Number Publication Date
RU2008114304A true RU2008114304A (ru) 2009-11-20

Family

ID=37708176

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008114304/13A RU2008114304A (ru) 2005-09-12 2006-06-01 Ингибирование вирусной экспрессии генов с использованием малой интерферирующей рнк

Country Status (9)

Country Link
EP (1) EP1979480A2 (de)
JP (1) JP2009521207A (de)
KR (1) KR20090003147A (de)
CN (2) CN102827841A (de)
AU (1) AU2006291568A1 (de)
BR (1) BRPI0615717A2 (de)
CA (1) CA2622242A1 (de)
RU (1) RU2008114304A (de)
WO (1) WO2007032794A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2624045C2 (ru) * 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042115A2 (en) * 2007-09-24 2009-04-02 Rosetta Inpharmatics Llc Methods of designing short hairpin rnas (shrnas) for gene silencing
JP2012504389A (ja) * 2008-09-22 2012-02-23 ダイセルナ ファーマシューティカルズ， インコーポレイテッド 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法
CN102245772A (zh) * 2008-10-15 2011-11-16 索马根尼科斯公司 抑制基因表达的短发卡rna
CN102325534B (zh) * 2008-12-18 2016-02-17 戴瑟纳制药公司 延长的dicer酶底物和特异性抑制基因表达的方法
WO2011008730A2 (en) 2009-07-13 2011-01-20 Somagenics Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
KR101668954B1 (ko) 2015-05-29 2016-10-24 연세대학교 산학협력단 ＨＣＶ ＩＲＥＳ를 표적으로 하는 Ｃ형 간염 바이러스 치료제 siRNA
WO2018112124A1 (en) * 2016-12-15 2018-06-21 Meharry Medical College Antiviral agents
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
UA127745C2 (uk) 2018-08-13 2023-12-20 Альнілам Фармасьютікалз, Інк. КОМПОЗИЦІЇ, ЩО МІСТЯТЬ ЗАСІБ НА ОСНОВІ dsRNA ВІРУСУ ГЕПАТИТУ В (HBV), ТА СПОСОБИ ЇХ ВИКОРИСТАННЯ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2457528C (en) * 2002-02-20 2011-07-12 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
EP1793835A4 (de) * 2004-09-10 2010-12-01 Somagenics Inc Kleine interferierende rnas zur effizienten verhinderung viraler genexpression und verwendungsverfahren dafür
CN100344331C (zh) * 2004-09-22 2007-10-24 广州拓谱基因技术有限公司 用于预防或治疗丙型肝炎的靶向小干扰rna制剂及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2624045C2 (ru) * 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
RU2745848C2 (ru) * 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)

Also Published As

Publication number Publication date
WO2007032794A2 (en) 2007-03-22
WO2007032794A3 (en) 2007-08-30
KR20090003147A (ko) 2009-01-09
CN101305095B (zh) 2012-09-26
BRPI0615717A2 (pt) 2011-05-24
EP1979480A2 (de) 2008-10-15
CN102827841A (zh) 2012-12-19
CN101305095A (zh) 2008-11-12
CA2622242A1 (en) 2007-03-22
AU2006291568A1 (en) 2007-03-22
JP2009521207A (ja) 2009-06-04

Similar Documents

Publication Publication Date Title
RU2008114304A (ru) Ингибирование вирусной экспрессии генов с использованием малой интерферирующей рнк
CA2165821C (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
Lin et al. Heterogeneous nuclear ribonuclear protein K interacts with the enterovirus 71 5′ untranslated region and participates in virus replication
AU2024203581A1 (en) Oligonucleotides for reduction of PD-L1 expression
Shi et al. Evidence for the Existence of a Pseudoknot Structure at the 3 ‘Terminus of the Flavivirus Genomic RNA
Serrano et al. The 3′ end of the foot-and-mouth disease virus genome establishes two distinct long-range RNA–RNA interactions with the 5′ end region
Lulla et al. Targeting the conserved stem loop 2 motif in the SARS-CoV-2 genome
James Aptamers in the virologists' toolkit
CN111876420A (zh) 一种小干扰核酸及组合物和应用
ES2639568T3 (es) Método para diseñar un régimen farmacológico para pacientes infectados con el VIH
US20060293267A1 (en) Dual functional oligonucleotides for use as anti-viral agents
US20170283802A1 (en) Design of nucleic acid binding molecules with non-watson crick and non-canonical pairing based on artificial mutation consensus sequences to counter escape mutations
US9328347B2 (en) siRNA useful in the treatment of flavivirus infection
Bassett et al. Lessons learned and yet-to-Be learned on the importance of RNA structure in SARS-CoV-2 replication
EP2071030A2 (de) Oligoribonukleotid- und Peptidnukleinsäure zur Hemmung der Aktivität des Hepatitis-C-Virus
CN107326067B (zh) 一种非酒精性脂肪肝的miRNA标记物
Blazquez et al. U1 interference (U1i) for antiviral approaches
US7776569B2 (en) Virally-encoded RNAs as substrates, inhibitors and delivery vehicles for RNAi
El Awady et al. Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells
Lulla et al. The stem loop 2 motif is a site of vulnerability for SARS-CoV-2
US20220119812A1 (en) Micro rna interactions as therapeutic targets for covid-19 and other viral infections
US20090203890A1 (en) Hepatitis c antivirals
RU2021122162A (ru) Новый коронавирус рыб
KR100435634B1 (ko) 제 1형 인간면역결핍 바이러스의 뉴클레오 캡시드 단백질에 결합하는 ｒｎａ
Baldassarre et al. Non-Coding RNAs and Innovative Therapeutic Strategies to Target the 5’UTR of SARS-CoV-2